리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 12월
페이지 정보:영문 192 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 펩타이드 치료제 시장은 2030년까지 563억 달러에 달할 전망
2024년에 437억 달러로 추정되는 세계의 펩타이드 치료제 시장은 2024년부터 2030년까지의 분석 기간 동안 CAGR 4.3%로 성장하여 2030년까지 563억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석 대상이 된 부문 중 하나인 혁신적 펩타이드 치료제는 CAGR 2.8%를 기록하며 분석 기간 종료시까지 299억 달러에 달할 것으로 예측됩니다. 한편 제네릭 펩타이드 치료제 부문의 성장률은 분석 기간 동안 CAGR 6.2%로 추정됩니다.
미국 시장은 115억 달러로 추정되는 한편 중국은 CAGR 7.4%로 성장할 것으로 예측됩니다
미국의 펩타이드 치료제 시장은 2024년에 115억 달러로 추정됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2024년부터 2030년까지의 분석 기간 동안 CAGR 7.4%를 기록하며 2030년까지 124억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장 분석으로는 일본과 캐나다가 있으며, 분석 기간 동안에 각각 CAGR 1.5%, 4.4%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 1.8%의 CAGR로 성장할 것으로 전망됩니다.
세계 펩타이드 치료제 시장 - 주요 시장 동향 및 촉진요인에 대한 개요
기술 발전은 펩타이드 치료제 개발을 어떻게 촉진하고 있는가?
기술의 발전으로 펩타이드 치료제의 개발이 크게 가속화되어 보다 안정적이고 강력하며 표적 지향적인 치료법을 개발할 수 있게 되었습니다. 펩타이드는 자연적으로 존재하는 생체분자로 체내에서 신호전달물질로 작용하며, 표적에 대한 높은 특이성을 보여 치료제 개발의 매력적인 후보물질로 각광받고 있습니다. 펩타이드 엔지니어링의 혁신으로 효소 분해에 내성이 있는 변형 펩타이드의 개발이 진행되어 생체 이용률 향상과 반감기 연장이 실현되었습니다. 이를 통해 투여 빈도를 줄일 수 있게 되었습니다. 또한, 나노입자 캡슐화 기술, 펩타이드 약물 복합체 등 전달 시스템의 발전으로 특정 조직이나 세포에 대한 표적 전달이 가능해져 펩타이드 기반 치료의 효과가 향상되고 있습니다. 펩타이드 구조를 안정화시키는 '펩타이드 스테이플링' 기술과 펩타이드 활성을 모방하면서 안정성을 높이는 '펩티도메틱' 활용도 펩타이드 치료제의 발전에 기여하고 있습니다. 이러한 혁신을 통해 대사질환에서 종양학, 감염질환에 이르기까지 다양한 질환을 보다 높은 효능과 적은 부작용으로 치료할 수 있는 펩타이드를 개발할 수 있게 되었습니다.
현대 의학에서 펩타이드 치료제가 주목받는 이유는 무엇일까?
펩타이드 치료제는 특정 수용체 및 세포 표적과 상호작용하는 독특한 능력으로 인해 현대 의학에서 큰 인기를 끌고 있습니다. 저분자 화합물이나 기존 생물학적 제제에서는 종종 달성할 수 없는 치료의 정밀도를 제공합니다. 펩타이드는 높은 특이성과 낮은 독성으로 알려져 있으며, 암, 심혈관질환, 대사성 질환 등 만성질환 치료에 특히 유망한 것으로 알려져 있습니다. 당뇨병 치료용 GLP-1 작용제, 심부전 치료용 바소프레신 수용체 길항제 등 펩타이드 기반 치료제는 눈에 띄는 효능을 보이며 임상현장에서의 채용이 활발히 이루어지고 있습니다. 또한, 펩타이드는 면역치료에 있어서도 그 역할이 점점 더 주목받고 있으며, 암이나 감염에 대한 면역반응을 유도하는 펩타이드 백신의 개발이 진행되고 있습니다. 대형 생물학적 제제에 비해 펩타이드의 제조 공정이 비교적 간단하고 확장성이 높기 때문에 의약품 개발에서 비용 효율적인 선택이 될 수 있습니다. 표적화되고 안전한 치료법에 대한 수요가 증가함에 따라 펩타이드 치료제는 주요 제약사의 개발 파이프라인에서 중요한 초점이 되고 있습니다.
업계 및 헬스케어 동향은 펩타이드 치료제 시장을 어떻게 형성하고 있을까?
산업 및 헬스케어 동향은 특히 맞춤형 의료 및 표적 치료의 부상과 함께 펩타이드 치료제 시장을 형성하는 데 중요한 역할을 하고 있습니다. 펩타이드는 질병 진행과 관련된 특정 분자 경로를 표적으로 삼을 수 있는 능력으로 인해 헬스케어 분야가 맞춤형 치료로 전환하는 과정에서 펩타이드는 필수 불가결한 존재가 되어가고 있습니다. 이는 특히 종양학에서 두드러지며, 펩타이드는 표적 약물전달 및 암 면역 치료제로 활용되고 있습니다. 만성질환, 특히 당뇨병과 비만의 유병률 증가도 펩타이드 치료제에 대한 관심을 높이고 있으며, GLP-1 유사체와 같은 약물이 이들 질환의 표준 치료제가 되고 있습니다. 또한, 생명공학 기술의 발전으로 안정성, 생체 이용률, 전달성 향상을 위한 펩타이드 변형이 용이해져 치료의 가능성이 확대되고 있습니다. 바이오로직스의 부상과 기존 치료제의 부작용을 줄이기 위한 노력과 맞물려 여러 치료 영역에서 펩타이드 의약품 개발이 더욱 가속화되고 있습니다.
펩타이드 치료제 시장의 성장을 이끄는 요인은 무엇일까?
펩타이드 치료제 시장의 성장은 기술 발전, 표적 치료에 대한 수요 증가, 만성질환 발생률 증가 등 여러 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 암, 대사성 질환, 심혈관질환 등의 치료에서 펩타이드의 활용 확대입니다. 이러한 질병에서 펩타이드의 높은 특이성과 낮은 독성은 눈에 띄는 치료 효과를 가져옵니다. 펩타이드의 안정화 및 전달에 관한 기술 혁신도 시장을 주도하고 있으며, 체내 지속성과 효능을 높인 펩타이드 개발을 가능하게 하고 있습니다. 또한, 맞춤의료에 대한 관심이 높아지면서 질병 진행에 관여하는 특정 경로를 표적으로 삼을 수 있는 펩타이드 기반 치료제에 대한 수요가 증가하고 있습니다. 특히 암과 감염성 질환에 대한 면역치료에 대한 관심이 높아진 것도 시장 확대에 기여하고 있으며, 이 분야에서 펩타이드 백신과 컨쥬게이트가 중요한 역할을 하고 있습니다. 또한, 대형 바이오의약품에 비해 펩타이드 치료제의 제조비용이 상대적으로 낮다는 점도 제약사들의 이 분야에 대한 투자 확대를 부추기며 펩타이드 치료제 시장의 성장을 더욱 가속화하고 있습니다.
부문:
유형(신규, 제네릭), 합성 기술(액상, 고체상, 하이브리드상), 용도(대사질환, 암, 심혈관질환, 항감염, 호흡기질환, 기타 용도)
조사 대상 기업 예시
AbbVie, Inc.
Advanced Accelerator Applications SA
Akashi Therapeutics, Inc.
Amgen, Inc.
Anthera Pharmaceuticals, Inc.
AstraZeneca PLC
Bachem AG
Bristol-Myers Squibb Company
Cardiorentis AG
Corden Pharma International GmbH
Debiopharm Group
Derma Sciences, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Hanmi Pharmaceutical Co., Ltd.
Insmed, Inc.
Ipsen Group
Johnson & Johnson
Lonza Group AG
Mallinckrodt PLC
Merck & Co., Inc.
MolMed S.p.A.
Novartis AG
Novo Nordisk A/S
Nymox Pharmaceutical Corporation
PAR Pharmaceutical Companies, Inc.
PeptiDream Inc.
Pfizer, Inc.
PolyPeptide Group
Radius Health, Inc.
Repligen Corporation
Sanofi SA
SciClone Pharmaceuticals Holding Limited.
Shire PLC
Takeda Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
The Medicines Company
X-GEN Pharmaceuticals, Inc.
Zealand Pharma A/S
Zydus Cadila
AI 통합
검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석을 혁신하고 있습니다.
Market Glass, Inc.는 LLM이나 산업별 SLM을 쿼리하는 일반적인 방식에 의존하는 대신, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색 엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.
관세 영향 계수
Market Glass, Inc.가 본사 소재지, 생산기지, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁 변화를 예측하면서 지리적 시장에 대한 관세의 영향을 반영하였습니다. 이러한 복잡하고 다면적인 시장 현실은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 경쟁사에게 다양한 영향을 미치며, 미시적 및 거시적 시장 역학에도 영향을 미칩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Peptide Therapeutics Market to Reach US$56.3 Billion by 2030
The global market for Peptide Therapeutics estimated at US$43.7 Billion in the year 2024, is expected to reach US$56.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Innovative Peptide Therapeutics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$29.9 Billion by the end of the analysis period. Growth in the Generic Peptide Therapeutics segment is estimated at 6.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$11.5 Billion While China is Forecast to Grow at 7.4% CAGR
The Peptide Therapeutics market in the U.S. is estimated at US$11.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$12.4 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.
Global Peptide Therapeutics Market - Key Trends & Drivers Summarized
How Are Technological Advances Enhancing Peptide Therapeutics Development?
The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing. Furthermore, advances in delivery systems, such as nanoparticle encapsulation and peptide-drug conjugates, are improving the effectiveness of peptide-based treatments by enabling targeted delivery to specific tissues or cells. Technologies such as peptide stapling, which stabilizes the peptide structure, and the use of peptidomimetics, which mimic peptide activity while enhancing stability, are also contributing to the growth of peptide therapeutics. These innovations are enabling the development of peptides that can treat a wide range of conditions, from metabolic disorders to oncology and infectious diseases, with greater efficacy and fewer side effects.
Why Are Peptide Therapeutics Gaining Popularity in Modern Medicine?
Peptide therapeutics are gaining significant popularity in modern medicine due to their unique ability to interact with specific receptors and cellular targets, offering precision in treatment that is often unmatched by small molecules or traditional biologics. Peptides are known for their high specificity and low toxicity, which makes them particularly attractive in the treatment of chronic diseases such as cancer, cardiovascular diseases, and metabolic disorders. Peptide-based therapies, including GLP-1 agonists for diabetes and vasopressin receptor antagonists for heart failure, have shown remarkable efficacy, driving their adoption in clinical settings. Additionally, peptides are increasingly being explored for their role in immunotherapy, with peptide vaccines being developed to trigger immune responses against cancers and infectious diseases. The relatively simple and scalable manufacturing processes for peptides compared to larger biologics also make them a cost-effective option for drug development. As the demand for targeted and safer therapies grows, peptide therapeutics are becoming a key focus in the development pipelines of major pharmaceutical companies.
How Are Industry and Healthcare Trends Shaping the Peptide Therapeutics Market?
Industry and healthcare trends are playing a significant role in shaping the peptide therapeutics market, particularly with the rise of personalized medicine and targeted therapies. As the healthcare sector shifts toward individualized treatments, peptides are becoming integral due to their ability to target specific molecular pathways associated with disease progression. This is particularly true in oncology, where peptides are being used for targeted drug delivery and as agents in cancer immunotherapies. The growing prevalence of chronic diseases, especially diabetes and obesity, has also led to increased interest in peptide therapeutics, with drugs like GLP-1 analogs becoming standard treatments for these conditions. Furthermore, advancements in biotechnology are making it easier to modify peptides for improved stability, bioavailability, and delivery, which is expanding their therapeutic potential. The rise of biologics and the focus on reducing the side effects associated with conventional therapies are further accelerating the development of peptide-based drugs across multiple therapeutic areas.
What Factors Are Driving Growth in the Peptide Therapeutics Market?
The growth in the peptide therapeutics market is driven by several factors, including technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. One of the primary drivers is the expanding use of peptides in the treatment of conditions like cancer, metabolic disorders, and cardiovascular diseases, where their high specificity and low toxicity provide significant therapeutic advantages. Technological innovations in peptide stabilization and delivery are also propelling the market, making it possible to develop peptides that are more durable and effective in the body. Additionally, the rising focus on personalized medicine is increasing the demand for peptide-based treatments, as they can be tailored to target specific pathways involved in disease progression. The growing interest in immunotherapy, particularly for cancer and infectious diseases, is also contributing to market expansion, with peptide vaccines and conjugates playing a crucial role in this space. Furthermore, the relatively lower production costs associated with peptide therapeutics compared to larger biologics are encouraging pharmaceutical companies to invest more heavily in this area, further driving growth in the peptide therapeutics market.
SCOPE OF STUDY:
The report analyzes the Peptide Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Innovative, Generic); Synthesis Technology (Liquid Phase, Solid Phase, Hybrid Phase); Application (Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory, Other Applications)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 33 Featured) -
AbbVie, Inc.
Advanced Accelerator Applications SA
Akashi Therapeutics, Inc.
Amgen, Inc.
Anthera Pharmaceuticals, Inc.
AstraZeneca PLC
Bachem AG
Bristol-Myers Squibb Company
Cardiorentis AG
Corden Pharma International GmbH
Debiopharm Group
Derma Sciences, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Hanmi Pharmaceutical Co., Ltd.
Insmed, Inc.
Ipsen Group
Johnson & Johnson
Lonza Group AG
Mallinckrodt PLC
Merck & Co., Inc.
MolMed S.p.A.
Novartis AG
Novo Nordisk A/S
Nymox Pharmaceutical Corporation
PAR Pharmaceutical Companies, Inc.
PeptiDream Inc.
Pfizer, Inc.
PolyPeptide Group
Radius Health, Inc.
Repligen Corporation
Sanofi SA
SciClone Pharmaceuticals Holding Limited.
Shire PLC
Takeda Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
The Medicines Company
X-GEN Pharmaceuticals, Inc.
Zealand Pharma A/S
Zydus Cadila
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
Global Economic Update
Peptide Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Chronic Diseases Drives Demand for Peptide-Based Therapeutics
Technological Advancements in Peptide Engineering and Modification Propel Development of Stable Therapeutics
Growing Adoption of Peptide Drugs in Oncology, Cardiovascular, and Metabolic Diseases Strengthens Market Growth
Increased Focus on Biologics and Targeted Drug Delivery Expands Opportunities for Peptide Therapeutics
Technological Innovations in Peptide Conjugation and Drug Delivery Systems Enhance Therapeutic Efficacy
Rising Use of Peptides in Immunotherapy and Cancer Vaccines Expands Market for Oncological Peptide Therapies
Growing Applications of Peptide Therapeutics in Hormone Replacement Therapy Drives Demand for Tailored Treatments
Technological Integration of Peptide-Based Therapeutics in Personalized Medicine Fuels Growth in Precision Healthcare
Increased Adoption of Long-Acting Peptide Drugs Expands Opportunities in Diabetes and Endocrine Disorders
Growing Focus on Peptide Therapeutics in Antimicrobial and Antiviral Applications Strengthens Market Potential
Rising Use of Peptide Drugs in Autoimmune Diseases and Inflammatory Conditions Expands the Therapeutic Landscape
Technological Advances in Peptide-Based Drug Delivery Systems, Including Nanocarriers and Hydrogels, Enhance Bioavailability
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Liquid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 2: World Historic Review for Liquid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 3: World 15-Year Perspective for Liquid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Solid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World Historic Review for Solid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 6: World 15-Year Perspective for Solid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Hybrid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 8: World Historic Review for Hybrid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 9: World 15-Year Perspective for Hybrid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 12: World 15-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 14: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 15: World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World Historic Review for Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 18: World 15-Year Perspective for Metabolic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 20: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 21: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 23: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 24: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Anti-Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 26: World Historic Review for Anti-Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 27: World 15-Year Perspective for Anti-Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 29: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 30: World 15-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 33: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 34: World Peptide Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 35: World Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Peptide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
JAPAN
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
CHINA
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
EUROPE
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Peptide Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
FRANCE
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
GERMANY
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
UNITED KINGDOM
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Spain 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Russia 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Peptide Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
AUSTRALIA
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Australia 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
INDIA
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 170: India Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: India 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: South Korea 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
LATIN AMERICA
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Peptide Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Latin America 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Argentina 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Brazil 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Mexico 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Latin America 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
MIDDLE EAST
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Peptide Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Middle East 15-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Iran 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Israel 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: Saudi Arabia 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: UAE 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Rest of Middle East 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030
AFRICA
Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2015, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 310: Africa 15-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2015, 2025 & 2030